Soligenix FY2026 EPS Estimate Lowered by Zacks Research

Soligenix Inc. (NASDAQ:SNGX) – Research analysts at Zacks Research cut their FY2026 EPS estimates for Soligenix in a research note issued on Monday, April 6th. Zacks Research analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings of ($1.14) per share for the year, down from their previous forecast of ($0.78). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Research also issued estimates for Soligenix’s FY2027 earnings at ($0.83) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.00.

Soligenix Price Performance

Shares of SNGX opened at $1.15 on Wednesday. The firm has a 50 day simple moving average of $1.16 and a two-hundred day simple moving average of $1.36. The company has a market cap of $11.86 million, a P/E ratio of -0.32 and a beta of 1.93. Soligenix has a one year low of $1.00 and a one year high of $6.23.

Institutional Investors Weigh In On Soligenix

Several hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in shares of Soligenix during the 4th quarter valued at $37,000. StoneX Group Inc. acquired a new stake in shares of Soligenix during the 4th quarter valued at $50,000. Geode Capital Management LLC boosted its holdings in shares of Soligenix by 88.8% during the 4th quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 37,811 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Soligenix during the 4th quarter valued at $51,000. Finally, Banco BTG Pactual S.A. acquired a new stake in shares of Soligenix during the 3rd quarter valued at $54,000. Institutional investors and hedge funds own 3.60% of the company’s stock.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.